New collective intelligence network to enable
the most advanced research in oncology in support of precision
medicine
BOSTON and ROLLE, Switzerland, May 30, 2024
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
healthcare technology company and a global leader in data-driven
medicine, today announced SOPHiA UNITY, a new data-driven
consortium designed to accelerate cancer research globally. SOPHiA
UNITY aims to bring together leading healthcare institutions to
progress a shared goal of furthering cancer research, advancing
drug development and supporting data-driven patient care.
To advance the adoption of precision oncology, it is crucial to
have access to large-scale data from a wide range of modalities
(such as imaging, genomics, pathology and clinical notes), and
diverse set of patient profiles. Currently, no single institution
globally collects the necessary volume and diversity of information
to propel the healthcare field forward. SOPHiA GENETICS has
launched SOPHiA UNITY to answer that need and meet the demand for
high-quality, diverse data at scale, aiming to drive a new era of
precision oncology research.
The collective intelligence network will advance research
initiatives using SOPHiA CarePath™, the multimodal module on the
SOPHiA DDM™ Platform, to aggregate and analyze complex real-world
data. This data will be harmonized and curated using SOPHiA
GENETICS' advanced AI-based technology and proprietary algorithms.
Through SOPHiA GENETICS' unique platform and
CarePath™ offering, SOPHiA UNITY members will have access to
meaningful, data-driven insights that will support decision-making
and expedite oncology research.
"At SOPHiA GENETICS, we have mastered the challenge of
harmonizing and connecting genomic data and have the capabilities
to do the same with other modalities through our CarePath™ module,"
said Jurgi Camblong, PhD., Co-founder and CEO of SOPHiA GENETICS.
"SOPHiA UNITY will usher in the next era of precision medicine
innovation by bringing together best-in-class institutions that are
committed to the advancement of oncology research and the use of
data-driven medicine. We are extremely optimistic about the
insights this collective intelligence network will generate to
further our shared goal."
SOPHiA GENETICS announced that the first member to join SOPHiA
UNITY is Memorial Sloan Kettering Cancer Center, a top cancer
treatment and research institution and world leader in patient
care, research, and educational programs. Additional members will
be announced in the coming months.
"I am looking forward to participating in the new data-driven
consortium and partnering with other institutions to draw deeper
insights from our collective data," said Mrinal Gounder, M.D., Sarcoma Oncologist &
Early Drug Development Specialist and Physician Ambassador to
India and Asia, Memorial Sloan Kettering Cancer
Center.
Leading academic cancer centers who are looking to connect with
like-minded researchers globally are eligible to join the SOPHiA
UNITY collective intelligence network and gather insights that can
be implemented locally. For more information, visit
SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to
data-driven medicine by using AI to deliver world-class care to
patients with cancer and rare disorders across the globe.
It is the creator of the SOPHiA DDM™ Platform, which analyzes
complex genomic and multimodal data and generates real-time,
actionable insights for a broad global network of hospital,
laboratory, and biopharma institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Memorial Sloan Kettering (MSK)
has institutional financial interests related to SOPHiA
GENETICS.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-global-consortium-sophia-unity-to-accelerate-cancer-research-drug-development-and-data-driven-patient-care-302159680.html
SOURCE SOPHiA GENETICS